Blood Test Shows Statistically Significant Association With Alzheimer's Disease (AD), May Predict Conversion Of Mild Cognitive Impairment To AD
Dr. Zsuzsanna Nagy of the University of Birmingham presented data from a clinical study, funded by Cytox Limited, demonstrating that a simple blood-based biomarker discriminated between patients with Alzheimer"s disease (AD) and control subjects. The findings were statistically highly significant, and the test discriminated between the two groups with 80% sensitivity and 80% specificity. The results also showed that 40% of the mild cognitive impairment (MCI) patients tested had the same test results as AD patients. Follow up study of MCI patients enrolled in an earlier study found that the test allowed early identification of those MCI patients who later developed dementia. The results were presented at the 2009 Alzheimer"s Association International Conference on Alzheimer"s Disease (ICAD 2009), held in Vienna, Austria.
Public Health